BioXcel Therapeutics, Inc. Net Income Loss

• BioXcel Therapeutics, Inc. showed a decrease of -17.3% in Net Income Loss from 2024 to 2025.
• This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Net Income Loss has declined by 1,439.9%.
• Historical annual values: Fiscal year 2025: -$69.90 million | Fiscal year 2024: -$59.60 million | Fiscal year 2023: -$179.05 million | Fiscal year 2022: -$165.76 million | Fiscal year 2021: -$106.93 million | Fiscal year 2020: -$82.17 million | Fiscal year 2019: -$32.97 million | Fiscal year 2018: -$19.27 million | Fiscal year 2017: -$4.54 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026